Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Items 201–300 of 1,002
Factors Associated with Vancomycin Nephrotoxicity in the Critically Ill
Hanrahan, T. P., Kotapati, C., Roberts, M. J., Rowland, J. L., Lipman, J., Roberts, J. A., & Udy, A. A. (2015) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1504300507 · Cited by 62
Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment
Flanagan, S., Minassian, S. L., Morris, D., Ponnuraj, R., Marbury, T. C., Alcorn, H. W., Fang, E., & Prokocimer, P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03431-14 · Cited by 62
Leone, S., Borrè, S., Monforte, A. D., Mordente, G., Petrosillo, N., Signore, A., Venditti, M., Viale, P., Nicastri, E., Lauria, F., et al. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.05.005 · Cited by 62
Nguyen, D. T., Yeh, E., Perry, S., Luo, R. F., Pinsky, B. A., Lee, B. P., Sisodiya, D., Baron, E. J., & Banaei, N. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02150-09 · Cited by 62
“In principle, the rapid availability of methicillin susceptibility results should allow clinicians to switch to more effective antibiotic therapy at an earlier time and thus improve clinical outcome, avoid drug toxicity, and minimize the risk for emergence of drug resistance (3, 28).”
BackgroundHanrahan, T. P., Whitehouse, T., Lipman, J., & Roberts, J. A. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.04.013 · Cited by 62
“/ International Journal of Antimicrobial Agents 46 (2015) 249–253 253”
BackgroundSong, K., Kim, H. B., Kim, H.-S., Lee, M. J., Jung, Y., Kim, G., Hwang, J.-H., Kim, N., Kim, M., Kim, C.-J., et al. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.09.010 · Cited by 62
Mogle, B. T., Steele, J. M., Seabury, R. W., Dang, U. J., & Kufel, W. D. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.08.024 · Cited by 63
Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs
Lê, J., & Bradley, J. S. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1128 · Cited by 62
Guo, T., van Hest, R. M., Roggeveen, L. F., Fleuren, L. M., Thoral, P., Bosman, R. J., van der Voort, P. H. J., Girbes, A. R. J., Mathôt, R. A. A., & Elbers, P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02543-18 · Cited by 64
“The recommended target ratio of an effective dosing regimen of vancomycin is 400 mg · h/liter or greater (1).”
BackgroundDavis, S. L., Scheetz, M. H., Bosso, J. A., Goff, D. A., & Rybak, M. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1327 · Cited by 61
“In 2009, an expert panel from the Infectious Diseases Society of America, American Society of Health-System Pharmacists, and Society of Infectious Diseases Pharmacists published vancomycin therapeutic guidelines providing consensus recommendations for vancomycin dosing and monitoring.(1) These guidelines were reinforc…”
BackgroundInfluentialSelf-citationVancomycin-Induced Neutropenia: Is it Dose- or Duration-Related?
Black, E., Lau, T. T. Y., & Ensom, M. H. H. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p583 · Cited by 61
Penetration of Vancomycin into Epithelial Lining Fluid in Healthy Volunteers
Lodise, T. P., Drusano, G. L., Butterfield, J. M., Scoville, J., Gotfried, M., & Rodvold, K. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00712-11 · Cited by 60
“Because MRSA has become such a likely culprit, vancomycin is recommended as firstline empirical therapy for patients with suspected or documented VAP (1, 20).”
BackgroundInfluentialPharmacokinetic considerations in pediatric pharmacotherapy
Lim, S. Y., & Pettit, R. S. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz161 · Cited by 65
Unbound fraction of vancomycin in intensive care unit patients
Kees, M. G., Wicha, S. G., Seefeld, A., Kees, F., & Kloft, C. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.175 · Cited by 60
Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess
Halilovic, J., Heintz, B. H., & Brown, J. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.03.013 · Cited by 60
“001) and were considered to be subtherapeutic per institutional and national guidelines.(16) Our institutional guidelines recommend that vancomycin dose be weight-based using either actual weight in non-obese individuals or adjusted body weight in obese individuals (15 mg/kg/dose in patients with normal renal function…”
BackgroundKnoderer, C. A., Nichols, K. R., Lyon, K. C., Veverka, M., & Wilson, A. C. (2013) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pit076 · Cited by 60
“The vancomycin serum trough concentration is an appropriate surrogate, and values of 15–20 mg/L in adult patients correlate with AUC/MIC of at least 400:1 for MRSA isolates with MIC values of ≥ 1 mg/L to vancomycin [3].”
BackgroundPharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
Takeda, Y., Matsumoto, K., Watanabe, E. M., Kanazawa, N., Fukamizu, T., Shigemi, A., Yokoyama, Y., Ikawa, K., & Morikawa, N. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s96143 · Cited by 68
“The guidelines for therapeutic drug monitoring of vancomycin suggest that an AUC/MIC ratio of $400 is the PK/PD parameter associated with clinical and bacteriological responses to vancomycin therapy.(6,7) Although optimized dosing regimens based on PK/PD are needed, the PK/PD analysis of teicoplanin against methicilli…”
BackgroundVancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population
Kishk, O. A., Lardieri, A. B., Heil, E. L., & Morgan, J. A. (2017) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-22.1.41 · Cited by 60
“Time to first negative blood culture,* days 1 (1-3) 2 (1-3) 0.”
BackgroundContinuous Versus Intermittent Vancomycin Infusions in Infants: A Randomized Controlled Trial
Gwee, A., Cranswick, N., McMullan, B. J., Perkins, E., Bolisetty, S., Gardiner, K., Daley, A. J., Ward, M. C., Chiletti, R., Donath, S. M., et al. (2019) · PEDIATRICS · doi:10.1542/peds.2018-2179 · Cited by 74
High-dose regimen to achieve novel target trough concentration in teicoplanin
Ueda, T., Takesue, Y., Nakajima, K., Ichki, K., Wada, Y., Komatsu, M., Tsuchida, T., Takahashi, Y., Ishihara, M., Kimura, T., et al. (2013) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2013.08.006 · Cited by 59
“In VCM, recent guidelines recommended a higher VCM Cmin of 15e20 mg/L to improve the clinical outcome of complicated MRSA infections [7].”
BackgroundFelton, T., Hope, W. W., & Roberts, J. A. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.04.007 · Cited by 73
“Other studies utilising TDM include β-lactams, vancomycin, teicoplanin and linezolid (Pea et al. 2003, 2006, 2010; Darley and MacGowan 2004; Rybak et al. 2009; Scaglione et al. 2009; Delattre et al. 2010; Roberts et al. 2010c; Udy et al. 2010).”
ResultHale, C. M., Seabury, R. W., Steele, J. M., Darko, W., & Miller, C. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190016642692 · Cited by 59
Tongsai, S., & Koomanachai, P. (2016) · BMC Research Notes · doi:10.1186/s13104-016-2252-7 · Cited by 63
Pais, G. M., Avedissian, S. N., O’Donnell, J. N., Rhodes, N. J., Lodise, T. P., Prozialeck, W. C., Lamar, P. C., Cluff, C., Gulati, A., Fitzgerald, J. C., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00079-19 · Cited by 59
Jacqz-Aigrain, É., Leroux, S., Thomson, A. H., Allegaert, K., Capparelli, E. V., Biran, V., Simon, N., Meibohm, B., Lo, Y. L., Marqués, R., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz158 · Cited by 59
Grimes, J., Desai, S. D., Charter, N. W., Lodge, J., Santos, R. M., Isidro‐Llobet, A., Mason, A. M., Wu, Z., Wolfe, L. A., Anantharaman, L., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.547 · Cited by 59
Pathogens Resistant to Antibacterial Agents
Chen, L. F., Chopra, T., & Kaye, K. S. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.002 · Cited by 76
“Recently, guidelines were published regarding optimal dosing of vancomycin for the treatment of infections caused by S aureus.(56)”
BackgroundKeyvani, F., GhavamiNejad, P., Saleh, M. A., Soltani, M., Zhao, Y., Sadeghzadeh, S., Shakeri, A., Chelle, P., Zheng, H., Rahman, F. A., et al. (2024) · Advanced Science · doi:10.1002/advs.202309027 · Cited by 69
Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis
Stockmann, C. R., Sherwin, C. M. T., Zobell, J. T., Lubsch, L. M., Young, D. C., Olson, J. A., Noyes, B. E., Ampofo, K., & Spigarelli, M. G. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1320 · Cited by 58
“The importance of proper vancomycin dosing has been highlighted in a consensus national guideline endorsed by several leading professional societies.(2) Guideline recommendations were supported by data from adults without CF.”
BackgroundOutpatient Parenteral Antimicrobial Therapy Practices among Adult Infectious Disease Physicians
Lane, M., Marschall, J., Beekmann, S. E., Polgreen, P. M., Banerjee, R., Hersh, A. L., & Babcock, H. M. (2014) · Infection Control and Hospital Epidemiology · doi:10.1086/676859 · Cited by 64
Synergy of ultrasound microbubbles and vancomycin against Staphylococcus epidermidis biofilm
Dong, Y., Chen, S., Wang, Z., Peng, N., & Yu, J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks490 · Cited by 58
Beyond Vancomycin: The Tail of the Lipoglycopeptides
Klinker, K. P., & Borgert, S. J. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.11.007 · Cited by 59
DeRyke, C. A., & Alexander, D. P. (2009) · Hospital Pharmacy · doi:10.1310/hpj4409-751 · Cited by 63
“The most recent vancomycin guidelines recommend loading doses of 25 to 30 mg/kg based on actual body weight for patients who are seriously ill.(17) Based on these recommendations, unconventionally high doses of 2 g or greater will be necessary in patients who are morbidly obese.”
BackgroundMethodInfluentialNigo, M., Rasmy, L., Mao, B., Kannadath, B. S., Xie, Z., & Zhi, D. (2024) · Nature Communications · doi:10.1038/s41467-024-46211-0 · Cited by 64
“Consideringthesideeffectpro fi leofvancomycinand the antibiotic stewardship standpoint, avoiding unnecessary anti-microbial therapy is highly desirable 4 .”
Gomes, D. M., Ward, K. E., & LaPlante, K. L. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1577 · Cited by 65
“Based on currently available data, clinicians should, with vigilance, continue to use 319 vancomycin per the Infectious Diseases Society of America guidelines.(2,3) Alternative therapies 320 should be considered in patients with risk factors for hVISA/VISA who are not responding 321”
BackgroundMethodThompson, J. M., Saini, V., Ashbaugh, A. G., Miller, R. J., Ordoñez, A. A., Ortines, R. V., Wang, Y., Sterling, R. S., Jain, S. K., & Miller, L. S. (2017) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.16.01002 · Cited by 62
Chen, Y., Wu, D., Dong, M., Zhu, Y., Lu, J., Li, X., Chen, C., & Li, Z. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2454-0 · Cited by 57
Continuous intravenous administration of vancomycin in medical intensive care unit patients
Saugel, B., Nowack, M., Hapfelmeier, A., Umgelter, A., Schultheiß, C., Thies, P., Phillip, V., Eyer, F., Schmid, R. M., & Huber, W. (2012) · Journal of Critical Care · doi:10.1016/j.jcrc.2012.02.003 · Cited by 56
“However, this target serum vancomycin trough concentration used in our study in the intV group is lower compared with more recent recommendations that were not yet available when the intV group patients analyzed in this study were treated [5,13].”
BackgroundResultInfluentialPark, K.-H., Kim, E. S., Kim, H. S., Park, S.-J., Bang, K. M., Park, H. J., Park, S.-Y., Moon, S. M., Chong, Y. P., Kim, S.-H., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks131 · Cited by 57
Herendael, B. V., Jeurissen, A., Tulkens, P. M., Vlieghe, E., Verbrugghe, W., Jorens, P. G., & Ieven, M. M. (2012) · Annals of Intensive Care · doi:10.1186/2110-5820-2-22 · Cited by 66
“Careful animal studies where T>MIC could be unambiguously separated from other PK parameters (which is difficult to obtain in human studies) showed that it is actually AUC24h/MIC (area under the curve over 24 h) that best predicts clinical efficacy [67-70].”
BackgroundPerformance of a vancomycin dosage regimen developed for obese patients
Reynolds, D. C., Waite, L. H., Alexander, D. P., & DeRyke, C. A. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110324 · Cited by 56
kamel, A. B., Bourguignon, L., Marcos, M., Ducher, M., & Goutelle, S. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000359 · Cited by 56
Hall, R. G., Hazlewood, K. A., Brouse, S. D., Giuliano, C. A., Haase, K. K., Frei, C. R., Forcade, N. A., Bell, T., Bedimo, R., & Álvarez, C. A. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-12 · Cited by 55
“5 mg/dl or 50% increase from baseline on at least two consecutive laboratory tests during the period from initiation of vancomycin to completion of therapy [6].”
BackgroundMethodInfluentialChin, S. J., Moore, G. A., Zhang, M., Clarke, H. D., Spangehl, M. J., & Young, S. W. (2018) · The Journal of Arthroplasty · doi:10.1016/j.arth.2018.03.013 · Cited by 56
Boot, W., Schmid, T., D’Este, M., Guillaume, O., Foster, A. L., Decosterd, L. A., Richards, R. G., Eglin, D., Zeiter, S., & Moriarty, T. F. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01840-20 · Cited by 59
“The average serum trough values of vancomycin achieved when administered twice a day were below desired targets (15 to 20mg/ml or area under the concentration-time curve [AUC] of 400mg·hour/ml) (26).”
BackgroundManagement and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens
Grgurich, P. E., Hudcova, J., Lei, Y., Sarwar, A., & Craven, D. E. (2012) · Expert Review of Respiratory Medicine · doi:10.1586/ers.12.45 · Cited by 61
Pletz, M. W., Burkhardt, O., & Welte, T. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-12-507 · Cited by 55
Wang, J., Wang, J., Fang, C., Chie, W., Lai, M., Lauderdale, T.-L. Y., Weng, C.-M., & Chang, S. (2010) · Journal of Infection · doi:10.1016/j.jinf.2010.09.029 · Cited by 59
Frymoyer, A. R., Guglielmo, B. J., Wilson, S. D., Scarpace, S. B., Benet, L. Z., & Hersh, A. L. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.871 · Cited by 54
A Randomized Trial of Loading Vancomycin in the Emergency Department
Rosini, J. M., Laughner, J., Levine, B. J., Papas, M. A., Reinhardt, J. F., & Jasani, N. B. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014556813 · Cited by 61
“This rate was not higher than the 5% to 7% incidence of nephrotoxicity referenced in the guidelines.(1,18,19) There was a higher incidence of nephrotoxicity in those receiving the standard dose of vancomycin, yet this was not statistically significant.”
BackgroundMethodResultInfluentialCasapao, A. M., Jacobs, D. M., Bowers, D. R., Beyda, N. D., Dilworth, T. J., & the REACH‐ID Study Group (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2034 · Cited by 55
Dosing vancomycin in the super obese: less is more
Crass, R. L., Dunn, R. D., Hong, J., Krop, L. C., & Pai, M. P. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky310 · Cited by 54
Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units
Kadambari, S., Heath, P. T., Sharland, M., Lewis, S., Nichols, A., & Turner, M. A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr351 · Cited by 54
Bounthavong, M., & Hsu, D. I. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903454912 · Cited by 53
Managing antimicrobial resistance in intensive care units
Gandhi, T. N., DePestel, D. D., Collins, C. D., Nagel, J. L., & Washer, L. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e6a2a4 · Cited by 57
“Examples include extended-interval aminoglycoside dosing (102), fluoroquinolone dosing (60, 103, 104), vancomycin dosing (105), and continuous or prolonged infusions of -lactams (106, 107).”
BackgroundHospitalist Perspective on the Treatment of Skin and Soft Tissue Infections
Amin, A., Cerceo, E. A., Deitelzweig, S. B., Pile, J. C., Rosenberg, D. J., & Sherman, B. M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.04.018 · Cited by 59
“Vancomycin doses of 15 to 20 mg/kg given every 8 to 12 hours are necessary for patients with normal renal function to achieve targeted serum trough levels when theMIC is 1 mg/mL or less.(13) Linezolid, an oral and IV oxazolidinone, was approved by the FDA in 2000 for uncomplicated skin and skin structure infections an…”
BackgroundRingenberg, T., Robinson, C. A., Meyers, R. S., Degnan, L., Shah, P. A., Siu, A., & Sturgill, M. G. (2015) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000664 · Cited by 53
“aureus isolates to vancomycin from less than or equal to 4 mcg/mL to less than or equal to 2 mcg/mL.(4,6,7) A current concern with vancomycin revolves around the nationwide increase in the MIC of MRSA, or the “MIC creep.”
BackgroundAonuma, K., Shiga, T., Atarashi, H., Doki, K., Echizen, H., Hagiwara, N., Hasegawa, J., Hayashi, H., Hirao, K., Ichida, F., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-66-0138 · Cited by 57
Smit, C., Wasmann, R. E., Goulooze, S. C., Wiezer, M. J., van Dongen, E. P. A., Mouton, J. W., Brüggemann, R. J. M., & Knibbe, C. A. J. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14144 · Cited by 54
“A comprehensive practice guideline published in 2009 advocated an efficacy target of AUC24h/ MIC ≥400 mg h L.(13) To reach this target with intermittent dose regimens, a target steady state trough concentration of 15–20 mg L was advised.”
BackgroundMethodInfluentialOda, K., Jono, H., Nosaka, K., & Saito, H. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106109 · Cited by 50
Prediction of vancomycin dose on high-dimensional data using machine learning techniques
Huang, X., Yu, Z. Y., Wei, X., Shi, J., Wang, Y., Wang, Z., Chen, J., Bu, S., Li, L., Gao, F., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1911642 · Cited by 56
“As one of the most frequent pathogens, MRSA infections increased by 1.28 times between 2007 and 2015 [5].”
BackgroundInfluentialAre Gentamicin and/or Vancomycin Associated with Ototoxicity in the Neonate? A Retrospective Audit
Vella-Brincat, J., Begg, E. J., Robertshawe, B. J., Lynn, A. M., Borrie, T. L., & Darlow, B. A. (2011) · Neonatology · doi:10.1159/000324857 · Cited by 52
“Vancomycin, a glycopeptide antibiotic, has also been associated with ototoxicity. In adults, the incidence of vancomycin-induced ototoxicity has been reported as 0–12p (with lower values when used alone, and higher when used with other ototoxic medications) [”
BackgroundFrymoyer, A. R., Hersh, A. L., Coralic, Z., Benet, L. Z., & Guglielmo, B. J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.005 · Cited by 52
“Based on the findings from studies in animals and adults, the best measure of vancomycin activity is AUC0–24/MIC.14,15 The achievement of an AUC0–24/MIC >400 in adults has been associated with optimal outcomes for the treatment of invasive MRSA infections.”
BackgroundPopulation Pharmacokinetics of Vancomycin in Thai Patients
Purwonugroho, T. A., Chulavatnatol, S., Preechagoon, Y., Chindavijak, B., Malathum, K., & Bunuparadah, P. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/762649 · Cited by 52
“On the basis of recent guideline [23], vancomycin trough concentration above 10 mg/L was recommended to avoid development of”
Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients
Chaijamorn, W., Jitsurong, A., Wiwattanawongsa, K., Wanakamanee, U., & Dandecha, P. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.04.010 · Cited by 52
Trough Concentrations of Vancomycin
Gordon, C. L., Thompson, C., Carapetis, J. R., Turnidge, J. D., Kilburn, C., & Currie, B. J. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31826a3eaf · Cited by 52
“Although increasing trough concentrations may be desirable for reasons of efficacy and resistance selection, the change is not currently supported by clinical trial data in adults or children.(3) Surprisingly, even before the recent emphasis on achieving higher trough vancomycin concentrations, there were only a very…”
MethodResultInfluentialApplying biomarkers to clinical practice: a guide for utilizing procalcitonin assays
Foushee, J. A., Hope, N. H., & Grace, E. E. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks265 · Cited by 63
Spapen, H. D., van Doorn, K. J., Diltoer, M., Verbrugghe, W., Jacobs, R., Dobbeleir, N., Honoré, P. M., & Jorens, P. G. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-26 · Cited by 52
“These observations have prompted experts to decrease the breakpoint of vancomycin susceptibility from 4 to 2 μg/mL and to recommend targeting serum vancomycin trough levels of 15-20 μg/mL for the treatment of methicillin-resistant SA (MRSA) pneumonia [3].”
BackgroundPharmacokinetics of vancomycin in adults receiving extracorporeal membrane oxygenation
Wu, C., Shen, L., Hsu, L.-F., Ko, W., & Wu, F. L. (2015) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2015.05.017 · Cited by 53
New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients
Cristallini, S., Hites, M., Kabtouri, H., Roberts, J. A., Beumier, M., COTTON, F. J., Lipman, J., Jacobs, F., Vincent, J., Créteur, J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00330-16 · Cited by 52
“The new dosage regimen tested in this study rapidly attained target serum vancomycin concentrations of 20 to 30 mg/liter; however, the pharmacodynamic (PD) index that drives drug effectiveness is the AUC0 –24/MIC ratio, in particular when it is 400 (30).”
BackgroundPais, G. M., Liu, J., Avedissian, S. N., Hiner, D., Xanthos, T. T., Chalkias, A. F., d’Aloja, E., Locci, E., Gilchrist, A., Prozialeck, W. C., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz563 · Cited by 55
Harigaya, Y., Bulitta, J. B., Forrest, A., Sakoulas, G., Lesse, A. J., Mylotte, J. M., & Tsuji, B. T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01585-08 · Cited by 55
“Recently published guidelines (1, 28, 38) support the notion of poor vancomycin penetration into ELF, citing that vancomycin is to be dosed to achieve high trough levels of 15 to 20 mg/liter for MRSA pneumonia, which has been adopted by some clinicians for all infection sources, with some institutions utilizing vancom…”
BackgroundMethodInfluentialVancomycin Monitoring in Children Using Bayesian Estimation
Lê, J., Ngu, B., Bradley, J. S., Murray, W. S., Nguyen, A., Nguyen, L., Romanowski, G. L., Vo, T., & Capparelli, E. V. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000039 · Cited by 51
“Furthermore, vancomycin AUC/MIC ratio $400 correlates to trough concentrations between 15 and 20 mcg/mL in adults.(2,3) Current Infectious Diseases Society of America guidelines recommend vancomycin 60 mg$kg21$d21 empirically for treating suspected serious MRSA infections in children to optimize vancomycin exposure.”
BackgroundInfluentialLi, J., Udy, A. A., Kirkpatrick, C. M. J., Lipman, J., & Roberts, J. A. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.08.017 · Cited by 51
Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review
Chastain, D. B., & Davis, A. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.023 · Cited by 51
Zhong, Q., Paredes, C. C., Zhang, S., & Rousk, J. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.124962 · Cited by 52
Snyder, A. D. H., Vidaillac, C., Rose, W. E., McRoberts, J. P., & Rybak, M. J. (2014) · Infectious Diseases and Therapy · doi:10.1007/s40121-014-0055-5 · Cited by 50
“5 mg/L; average half-life 3 h; protein binding 80%) [21– 23], and VAN 2 g q12h (fCmax 30 mg/L; average half-life 6 h; protein binding 50%) [24, 25] alone or in combination with CLA 250 mg q12h or RIF 600 mg q24h.”
BackgroundSelf-citationPai, M. P., Russo, A., Novelli, A., Venditti, M., & Falcone, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02355-14 · Cited by 50
“Identification of daptomycin AUC24 target values for different MRSA-related infections and patient populations will contribute to improve dosing strategies, as has been the case for aminoglycosides and vancomycin (4, 5).”
BackgroundMethodPatel, M. (2009) · Drugs · doi:10.2165/00003495-200969060-00004 · Cited by 58
Tseng, S. H., Lim, C. P., Chen, Q., Tang, C. C., Kong, S. T., & Ho, P. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01647-17 · Cited by 50
Vancomycin Dosing in Patients on Intermittent Hemodialysis
Vandecasteele, S. J., & Vriese, A. S. D. (2011) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00803.x · Cited by 49
Optimization of time to initial vancomycin target trough improves clinical outcomes
Cardile, A. P., Tan, C., Lustik, M. B., Stratton, A., Madar, C., Elegino, J., & Hsue, G. (2015) · SpringerPlus · doi:10.1186/s40064-015-1146-9 · Cited by 49
“Vancomycin dosing and drug monitoring has been the subject of deliberation over the years (Rybak et al. 2009).”
InfluentialLeonard, S. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042103 · Cited by 53
“5 mg/mL, half-life: 6 h; at 50% protein binding for vancomycin these levels correspond to a total Cmax of 60 mg/mL and Cmin of 15 mg/mL) [30], nafcillin 2 g every 4 h (targets: fCmax: 5.”
BackgroundMason, E. O., Lamberth, L. B., Hammerman, W. A., Hultén, K. G., Versalovic, J. A., & Kaplan, S. L. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00407-09 · Cited by 56
“Etest 1 0 0 0 4 (44) 4 (44) 1 (11) 2 0 0 1 (8) 6 (50) 4 (33) 1 (8) 3 0 0 3 (14) 11 (43) 16 (29) 5 (14) 4 0 0 1 (3) 11 (23) 19 (63) 5 (11) 5 0 0 2 (8) 5 (35) 16 (42) 4 (15) 6 0 0 0 1 (13) 26 (77) 1 (10) 7 0 0 0 1 (6) 16 (88) 1 (6)”
da Silva, L. V., Araújo, M. T., dos Santos, K. R. N., & Nunes, A. P. F. (2011) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762011000100007 · Cited by 52
Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice
Elbarbry, F. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0456-4 · Cited by 49
“The current vancomycin dosing and monitoring guidelines are based on a consensus statement of the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), and the Society of Infectious Diseases Pharmacists (SIDP) that was published in 2009 [2].”
BackgroundMethodResultInfluentialBiopsy-proven vancomycin-induced acute kidney injury: a case report and literature review
Sawada, A., Kawanishi, K., Morikawa, S., Nakano, T., Kodama, M., Mitobe, M., Taneda, S., Koike, J., Ohara, M., Nagashima, Y., et al. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0845-1 · Cited by 51
“24 μg/mL, 15–20 μg/mL is for complicated infections [12]) and sCr stable (83.”
BackgroundUeda, T., Takesue, Y., Nakajima, K., Ichiki, K., Ishikawa, K., Takai, Y., Yamada, K., Tsuchida, T., Otani, N., Takahashi, Y., et al. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00424-3 · Cited by 49
International survey of antibiotic dosing and monitoring in adult intensive care units
Williams, P. G., Tabah, A., Cotta, M. O., Sandaradura, I., Kanji, S., Scheetz, M. H., Imani, S., Elhadi, M. K., Luque, S., Schellack, N., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04527-1 · Cited by 56
“aureus infections is established as an AUC/MIC of 400–600 mg·h/L [27].”
BackgroundHong, J., Krop, L. C., Johns, T. L., & Pai, M. P. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1588 · Cited by 48
Nailor, M. D., & Sobel, J. D. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.010 · Cited by 54
Li, X., Wang, F., Xu, B., Yu, X., Yang, Y., Zhang, L., & Huan-de, L. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.08.002 · Cited by 48
Late-Occurring Vancomycin-Associated Acute Kidney Injury in Children Receiving Prolonged Therapy
Knoderer, C. A., Gritzman, A. L., Nichols, K. R., & Wilson, A. C. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015594190 · Cited by 48
“Patients in the final analysis had a median (IQR) age (years) of 2 (1-7) with a minimum to maximum age of 1 month to 17 years.”
Introducing MINA – The Molecularly Imprinted Nanoparticle Assay
Shutov, R. V., Guerreiro, A. R., Moczko, E., de Vargas-Sansalvador, I. M. P., Chianella, I., Whitcombe, M. J., & Piletsky, S. A. (2014) · Small · doi:10.1002/smll.201301996 · Cited by 48
Vancomycin is commonly under‐dosed in critically ill children and neonates
Sosnin, N., Curtis, N. C., Cranswick, N., Chiletti, R., & Gwee, A. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14084 · Cited by 48
“AUC24/ MIC).(23) This is based on studies of S.”
MethodJelliffe, R. W., Schumitzky, A., Bayard, D., Fu, X., & Neely, M. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000168 · Cited by 47
Giachetto, G., Telechea, H., Speranza, N., Oyarzun, M., Nanni, L., & Menchaca, A. (2010) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181fe4047 · Cited by 50
“Old age, prolonged treatment, and Cmin 30 g/mL are risk factors identified for nephrotoxicity (25).”
BackgroundEvaluation of teicoplanin dosing designs to achieve a new target trough concentration
Ueda, T., Takesue, Y., Nakajima, K., Ichki, K., Wada, Y., Tsuchida, T., Takahashi, Y., Ishihara, M., Tatsumi, S., Kimura, T., et al. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-011-0325-z · Cited by 47
“5 mg/dL or 50% increase from the baseline [11].”
BackgroundGhosh, N., Chavada, R., Maley, M. W., & van Hal, S. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12695 · Cited by 47
Artificial Macrocycles by Ugi Reaction and Passerini Ring Closure
Abdelraheem, E. M. M., Kurpiewska, K., Kalinowska‐Tłuścik, J., & Dömling, A. S. S. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b01430 · Cited by 47
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.